A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

July 31, 2027

Conditions
Polycythemia Vera
Interventions
DRUG

P1101 (Ropeginterferon alfa-2b-njft)

Ropeginterferon alfa-2b-njft

DRUG

Ropeginterferon alfa-2b-njft (P1101)

Ropeginterferon alfa-2b-njft

Trial Locations (23)

10029

Mount Sinai, New York

10467

Montefiore Medical Center, The Bronx

20817

American Oncology Partners of Maryland PA (Center for Cancer & Blood Disorders), Bethesda

22903

University of Virginia - Emily Couric Cancer Center, Charlottesville

27265

Wake Forest Baptist Medical Center, High Point

27599

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill

27834

East Carolina University, Greenville

32207

Baptist MD Anderson, Jacksonville

38103

University of Tennessee Health Science Center, Memphis

42003

Mercy Health, Paducah

46804

Fort Wayne Medical Oncology and Hematology, Fort Wayne

63110

Washington University School of Medicine, St Louis

66205

University of Kansas Medical Center, Westwood

70112

Tulane University Medical Center, New Orleans

77030

MD Anderson, Houston

841312

University of Utah, Salt Lake City

08816

Astera HealthCare, East Brunswick

Unknown

Tom Baker Cancer Centre, Calgary

St. Paul's Hospital, Vancouver

Juravinski Cancer Center - Hamilton Health Sciences, Hamilton

Princess Margaret Hospital, Toronto

K1H 8L6

The Ottawa Hospital, Ottawa

M5B 1W8

St. Michael's Hospital, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PharmaEssentia

INDUSTRY